Understanding these interactions facilitates the development of targeted therapies such as AR inhibitors, PI3K inhibitors, and PARP inhibitors that disrupt key hormonal and genetic drivers of PCa progression (Antonarakis et al., 2020; Crumbaker et al., 2017). Here, PIK3CA is linked to posterior cortical atrophy.